How I treat rare venous thromboses

Blood

Volumn 112, Issue 13, 2008, Pages 4818-4823

  Martinelli, Ida ^a   Franchini, Massimo ^b   Mannucci, Pier Mannuccio ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; HEPARIN; HYDROXYUREA; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; CEREBRAL VEIN THROMBOSIS; CLINICAL FEATURE; CONSENSUS; DEEP VEIN THROMBOSIS; HUMAN; POINT MUTATION; PRIORITY JOURNAL; RISK FACTOR; SPLANCHNIC VEIN THROMBOSIS; THROMBOPHILIA; VEIN DISEASE; VEIN THROMBOSIS; ALGORITHM; BRAIN VEIN; DISEASE MANAGEMENT; OCCLUSIVE CEREBROVASCULAR DISEASE; REVIEW; SPLANCHNIC BLOOD FLOW;

ALGORITHMS; CEREBRAL VEINS; DISEASE MANAGEMENT; HUMANS; INTRACRANIAL THROMBOSIS; SPLANCHNIC CIRCULATION; VENOUS THROMBOSIS;

EID: 58149386405     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-165969     Document Type: Article

References (55)

1. Martinelli I. Unusual forms of venous thrombosis and thrombophilia. Pathophysiol Haemost Thromb. 2002;32:343-345.
2. Lussana F, Dentali F, Ageno W, Kamphuisen PW. Venous thrombosis at unusual sites and the role of thrombophilia. Semin Thromb Haemost. 2007;33:582-587.
3. Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664-670.
4. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352:1791-1798.
5. Dentali F, Gianni M, Crowther MA, Ageno W. Natural history of cerebral vein thrombosis: a systematic review. Blood. 2006;108:1129-1134.
6. Stam J, de Bruijn SF, DeVeber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database Syst Rev. 2002;4:CD002005.
7. de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. Br Med J. 1998;316:589-592.
8. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338:1793-1797.
9. Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci PM. Hyperhomocysteinemia in cerebral vein thrombosis. Blood. 2003;102:1363-1366.
10. Gadelha T, Andre C, Juca AA, Nucci M. Prothrombin 20210A and oral contraceptive use as risk factors for cerebral venous thrombosis. Cerebrovasc Dis. 2005;19:49-52.
11. Rodrigues CA, Rocha LK, Morelli VM, Franco RF, Lourenço DM. Prothrombin G20210A mutation, and not factor V Leiden mutation, is a risk factor for cerebral venous thrombosis in Brazilian patients. J Thromb Haemost. 2004;2:1211-1212.
12. Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol. 2002;70:126-132.
13. Boncoraglio G, Carriero MR, Chiapparini L, et al. Hyperhomocysteinemia and other thrombophilic risk factors in 26 patients with cerebral venous thrombosis. Eur J Neurol. 2004;11:405-409.
14. Ventura P, Cobelli M, Marietta M, Panini R, Rosa MC, Salvioli G. Hyperhomocysteinemia and other newly recognized inherited coagulation disorders (factor V Leiden and prothrombin gene mutation) in patients with idiopathic cerebral vein thrombosis. Cerebrovasc Dis. 2004;17:153-159.
15. Bugnicourt JM, Roussel B, Tramier B, Lamy C, Godefroy O. Cerebral venous thrombosis and plasma concentrations of factor VIII and von Willebrand factor: a case-control study. J Neurol Neurosurg Psychiatry. 2007;78:699-701.
16. Voetsch B, Jin RC, Bierl C, et al. Role of promoter polymorphisms in the plasma glutathione peroxi-dase (GPx-3) gene as a risk factor for cerebral venous thrombosis. Stroke. 2008;39:303-307.
17. Lichy C, Dong-Si T, Reuner K, et al. Risk of cerebral venous thrombosis and novel gene polymorphisms of the coagulation and fibrinolytic systems. J Neurol. 2006;253:316-320.
18. Libourel EJ, ten Kate MK, Brouwer JL, Veeger NJ, van der Meer J. Contribution of multiple thrombophiliac and transient risk factors in the development of cerebral vein thrombosis. Thromb Res. 2007;121:301-307.
19. Dentali F, Crowther M,Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood. 2006;107:2766-2773.
20. Masuhr F, Einhäupl K. Treatment of cerebral venous and sinus thrombosis. Front Neurol Sci. 2008;23:132-143.
21. Ferro JM, Canhao P. Acute treatment of cerebral venous and dural sinus thrombosis. Curr Treat Options Neurol. 2008;10:126-137.
22. Einhaupl KM, Villringer A, Meister W et al. Hepa-rin treatment in sinus venous thrombosis. Lancet. 1991;338:597-600.
23. de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke. 1999;30:484-488.
24. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:630S-339S.
25. Einhäupl K, Bousser MG, de Bruijn SF, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis. Eur J Neurol. 2006;13:553-559.
26. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, HadengueA, Valla DC. Budd-Chiari syndrome: a review by an expert panel. J Hepatol. 2003;38:364-371.
27. Valla D. Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus West. J Gastroen-terol Hepatol. 2004;19:S204-S211.
28. De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Haemost. 1997;23:411-418.
29. James C, Ugo V, Le Couedic JP, et al.Aunique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1448.
30. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44:1528-1534.
31. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost. 2007;5:708-714.
32. Colaizzo D, Amitrano L, Tiscia GL, Grandone E, Guardascione MA, Margaglione M.Anew JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood. 2007;110: 2768-2769.
33. Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case control study. Blood. 2000;96:2364-2368.
34. Primignani M, Martinelli I, Bucciarelli P, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology. 2005;41:603-608.
35. Amitrano L, Brancaccio V, Guardascione MA, et al. High prevalence of thrombophilic genotypes in patients with acute mesenteric vein thrombosis. Am J Gastroenterol. 2001;96:146-149.
36. Denninger MH, Chaït Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000;31:587-591.
37. Madonna P, De Stefano V, Coppola A, Cerbone AM, Di Minno G. G20210A prothrombin gene mutation and other trombophilic polymorphisms in patients with portal or hepatic venous thrombosis. Gastroenterology. 2001;120:1059-1060.
38. Sharma S, Texeira A, Texeira P, Elias E, Wilde J, Olliff SP. Pharmacological thrombolysis in Budd Chiari syndrome: a single centre experience and review of the literature. J Hepatol. 2004;40:172-180.
39. Amitrano L, Guardascione MA, Scaglione M, et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol. 2007;192:2464-2470.
40. Webster GJ, Burroughs AK, Riordan SM. Review article: portal vein thrombosis - new insights into aetiology and management. Aliment Pharmacol Ther. 2005;21:1-9.
41. Sarin SK, Sollano JD, Chawla YK, et al; Members of the APASL Working Party on Portal Hypertension. Consensus on extra-hepatic portal vein obstruction. Liver International. 2006;26:512-519.
42. Bernardi E, Pesavento R, Prandoni P. Upper extremity deep venous thrombosis. Semin Thromb Haemost. 2006;32:729-736.
43. Martinelli I, Cattaneo M, Panzeri D, Taioli E, Mannucci PM. Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med. 1997;126:707-711.
44. Martinelli I, Battaglioli T, Bucciarelli P, Passamonti SM, Mannucci PM. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation. 2004;110:566-570.
45. Prandoni P, Bernardi E, Marchiori A, et al. The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. Br Med J. 2004;329:484-485.
46. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Old and new risk factors for upper extremity deep venous thrombosis. J Thromb Haemost. 2005;3: 2471-2478.
47. Baarslag HJ, Koopman MM, Hutten BA, et al. Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremity: survival, risk factors and post-thrombotic syndrome. Eur J Intern Med. 2004;15:503-507.
48. Chan W-S, Ginsberg JS. Areview of upper extremity deep vein thrombosis in pregnancy: unmasking the "ART" behind the clot. J Thromb Haemost. 2006;4:1673-1677.
49. Bauersachs RM, Manolopoulos K, Hoppe I,Arin MJ, Schleussner E. The "ART" behind the clot: solving the mystery. J Thromb Haemost. 2007;5: 438-439.
50. Kearon C, Kahn S,Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:454S-545S.
51. Lechner D, Wiener C, WeltermannA, Eischer L, Eichinger S, Kyrle PA. Comparison between idio-pathic deep vein thrombosis of the upper and lower extremity regarding risk factors and recurrence. J Thromb Haemost. 2008;6:1269-1274.
52. Heron E, Lozinguez O, Alhenc Gelas M, Emmerich J, Fiessinger JN. Hypercoagulable states in primary upper extremity deep vein thrombosis. Arch Intern Med. 2000;160:382-386.
53. Hendler MF, Meschengieser SS, Blanco AN, et al. Primary upper-extremity deep vein thrombosis: high prevalence of thrombophilic defects. Am J Hematol. 2004;76:330-337.
54. Leebeek FW, Stadhouders NA, van Stein D, Gómez-García EB, Kappers-Klunne MC. Hyper-coagulability states in upper-extremity deep venous thrombosis.Am J Hematol. 2001;67:15-19.
55. Vaya A, Mira Y, Mateo J, et al. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. Thromb Haemost. 2003;89:452-457.